KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 78 filers reported holding KINNATE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $203,669 | -53.7% | 145,478 | +0.3% | 0.00% | – |
| Q2 2023 | $439,626 | -21.9% | 145,091 | +61.1% | 0.00% | – |
| Q1 2023 | $563,031 | +100.4% | 90,085 | +283.3% | 0.00% | – |
| Q3 2022 | $281,000 | -39.4% | 23,500 | -36.2% | 0.00% | – |
| Q2 2022 | $464,000 | +102.6% | 36,830 | +81.4% | 0.00% | – |
| Q1 2022 | $229,000 | -44.4% | 20,300 | -12.8% | 0.00% | – |
| Q4 2021 | $412,000 | – | 23,280 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |